Idogen – The Q3 quarterly report

Meet and ask questions to CEO, Anders Karlsson when he presents the quarterly Q3 report.

Idogen is a Swedish Biotech company. The company develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues. The term “tolerogenic” refers to the immune system’s selective tolerance of a specific pathogenic or immune activating antigen following treatment with Idogen’s therapy.

The company announce the result the 26th in the morning.